Form D · Pharmaceuticals

MBX Biosciences, Inc.

Carmel, IN · CIK 0001776111

Offering snapshot reported Nov 18, 2022 · SEC filing

Reported sold
$46.7M
Offering amount: $115M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 7, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 18, 2022Initial$46,675,441No comparison20SEC filing
Jul 27, 2020Initial$25,822,235No comparison16SEC filing
May 10, 2019Initial$23,000,000No comparison9SEC filing
May 10, 2019Amendment$2,300,000-$20,700,000vs May 10, 20199SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-465364
Amount sold includes $10,184,444 from conversion of promissory notes

Source: Form D, filed Nov 18, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tiba Aynechi Director
Richard Bartram Executive
James M. Cornelius Director
Richard Di Marchi Director, Executive
Carl Gordon Director
Peter Kent Hawryluk Director, Executive
Patrick Heron Director
Timothy Knickerbocker Director, Executive
Edward Mathers Director
Ora Pescovitz Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
11711 N. Meridian Street, Suite 300
Carmel, IN, 46032